MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 463902 | Name: Nialamide
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Nialamide is a non-selective, irreversible monoamine oxidase inhibitor (MAOI) of the hydrazine class that was used as an antidepressant. It was withdrawn by Pfizer several decades ago due to the risk of hepatotoxicity. The antiatherogenic activity of nialamide was used to design pyridinolcarbamate.

Chemical Structure

Nialamide
CAS#51-12-7

Theoretical Analysis

MedKoo Cat#: 463902

Name: Nialamide

CAS#: 51-12-7

Chemical Formula: C16H18N4O2

Exact Mass: 298.1430

Molecular Weight: 298.35

Elemental Analysis: C, 64.41; H, 6.08; N, 18.78; O, 10.73

Price and Availability

Size Price Availability Quantity
1g USD 350.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
Nialamide; Delmoneurina; Espril; Nialamid; Novazid; NSC 124514; NSC-124514; NSC124514; Surgex; Nuredal;
IUPAC/Chemical Name
N-benzyl-3-(2-isonicotinoylhydrazinyl)propanamide
InChi Key
NOIIUHRQUVNIDD-UHFFFAOYSA-N
InChi Code
InChI=1S/C16H18N4O2/c21-15(18-12-13-4-2-1-3-5-13)8-11-19-20-16(22)14-6-9-17-10-7-14/h1-7,9-10,19H,8,11-12H2,(H,18,21)(H,20,22)
SMILES Code
O=C(NCc1ccccc1)CCNNC(c2ccncc2)=O
Appearance
Solid powder
Purity
>95% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
Nialamide is a non-selective, irreversible monoamine oxidase inhibitor (MAOI) of the hydrazine class.
In vitro activity:
TBD
In vivo activity:
Rats were given subcutaneously 50 mg/kg body weight of nialamide in depot form every other day after 25 weeks of oral treatment with MNNG. Prolonged alternate-day administration of nialamide caused a significant increase in the incidence and number of gastric cancers of the glandular stomach in week 52. Nialamide also caused a significant increase in tissue norepinephrine concentrations in the gastric wall and in the labeling indices of the gastric mucosae. Reference: Jpn J Cancer Res. 1989 Jun;80(6):521-5. https://pubmed.ncbi.nlm.nih.gov/2503473/
Solvent mg/mL mM comments
Solubility
DMSO 100.0 335.18
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 298.35 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Tatsuta M, Iishi H, Baba M, Taniguchi H. Promotion by nialamide of gastric carcinogenesis induced by N-methyl-N'-nitro-N-nitrosoguanidine in Wistar rats. Jpn J Cancer Res. 1989 Jun;80(6):521-5. doi: 10.1111/j.1349-7006.1989.tb01670.x. PMID: 2503473; PMCID: PMC5917799. 2. Lopez Aliaga I, Reche A, Barrionuevo M, Campos MS. Influence of an inhibitor of monoaminooxidase (nialamide) on the serum levels, urinary excretion and plasma clearance of urea, uric acid and creatinine in adult and growing rats. Nahrung. 1989;33(6):575-81. PMID: 2797116.
In vitro protocol:
TBD
In vivo protocol:
1. Tatsuta M, Iishi H, Baba M, Taniguchi H. Promotion by nialamide of gastric carcinogenesis induced by N-methyl-N'-nitro-N-nitrosoguanidine in Wistar rats. Jpn J Cancer Res. 1989 Jun;80(6):521-5. doi: 10.1111/j.1349-7006.1989.tb01670.x. PMID: 2503473; PMCID: PMC5917799. 2. Lopez Aliaga I, Reche A, Barrionuevo M, Campos MS. Influence of an inhibitor of monoaminooxidase (nialamide) on the serum levels, urinary excretion and plasma clearance of urea, uric acid and creatinine in adult and growing rats. Nahrung. 1989;33(6):575-81. PMID: 2797116.
1: Domínguez-Rodríguez LE, Stecina K, García-Ramírez DL, Mena-Avila E, Milla- Cruz JJ, Martínez-Silva L, Zhang M, Hultborn H, Quevedo JN. Candidate Interneurons Mediating the Resetting of the Locomotor Rhythm by Extensor Group I Afferents in the Cat. Neuroscience. 2020 Dec 1;450:96-112. doi: 10.1016/j.neuroscience.2020.09.017. Epub 2020 Sep 15. PMID: 32946952. 2: Liu Y, Feng S, Subedi K, Wang H. Attenuation of Ischemic Stroke-Caused Brain Injury by a Monoamine Oxidase Inhibitor Involves Improved Proteostasis and Reduced Neuroinflammation. Mol Neurobiol. 2020 Feb;57(2):937-948. doi: 10.1007/s12035-019-01788-2. Epub 2019 Oct 15. PMID: 31620993; PMCID: PMC7035161. 3: Wang BS, Liu Z, Sun SL, Zhao Y. Identification of genes and candidate agents associated with pancreatic cancer. Tumour Biol. 2014 Jan;35(1):81-8. doi: 10.1007/s13277-013-1009-3. Epub 2013 Aug 10. PMID: 23934415. 4: Ahmad S, Hughes MA, Yeh LA, Scott JE. Potential repurposing of known drugs as potent bacterial β-glucuronidase inhibitors. J Biomol Screen. 2012 Aug;17(7):957-65. doi: 10.1177/1087057112444927. Epub 2012 Apr 24. PMID: 22535688. 5: Meehan CF, Grondahl L, Nielsen JB, Hultborn H. Fictive locomotion in the adult decerebrate and spinal mouse in vivo. J Physiol. 2012 Jan 15;590(2):289-300. doi: 10.1113/jphysiol.2011.214643. Epub 2011 Nov 21. PMID: 22106172; PMCID: PMC3285065. 6: Fuxe K, Dahlström AB, Jonsson G, Marcellino D, Guescini M, Dam M, Manger P, Agnati L. The discovery of central monoamine neurons gave volume transmission to the wired brain. Prog Neurobiol. 2010 Feb 9;90(2):82-100. doi: 10.1016/j.pneurobio.2009.10.012. Epub 2009 Oct 21. PMID: 19853007. 7: Huang L, Marzan F, Jayewardene AL, Lizak PS, Li X, Aweeka FT. Development and validation of a hydrophilic interaction liquid chromatography-tandem mass spectrometry method for determination of isoniazid in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Jan 15;877(3):285-90. doi: 10.1016/j.jchromb.2008.12.024. Epub 2008 Dec 24. PMID: 19112051; PMCID: PMC3032609. 8: Koval'chuk VV. [Pharmacologic correction of psycho-emotive disorders in the rehabilitation of patients after removal of brain tumors]. Vopr Onkol. 2007;53(6):704-10. Russian. PMID: 18416142. 9: Bilkei-Gorzo A, Michel K, Noble F, Roques BP, Zimmer A. Preproenkephalin knockout mice show no depression-related phenotype. Neuropsychopharmacology. 2007 Nov;32(11):2330-7. doi: 10.1038/sj.npp.1301370. Epub 2007 Mar 21. PMID: 17375141. 10: Nielsen JB, Conway BA, Halliday DM, Perreault MC, Hultborn H. Organization of common synaptic drive to motoneurones during fictive locomotion in the spinal cat. J Physiol. 2005 Nov 15;569(Pt 1):291-304. doi: 10.1113/jphysiol.2005.091744. Epub 2005 Sep 15. PMID: 16166163; PMCID: PMC1464221. 11: Schomburg ED, Steffens H, Wada N. Parallel nociceptive reflex pathways with negative and positive feedback functions to foot extensors in the cat. J Physiol. 2001 Oct 15;536(Pt 2):605-13. doi: 10.1111/j.1469-7793.2001.0605c.xd. PMID: 11600693; PMCID: PMC2278868. 12: Jansson A, Tinner B, Bancila M, Vergé D, Steinbusch HW, Agnati LF, Fuxe K. Relationships of 5-hydroxytryptamine immunoreactive terminal-like varicosities to 5-hydroxytryptamine-2A receptor-immunoreactive neuronal processes in the rat forebrain. J Chem Neuroanat. 2001 Sep;22(3):185-203. doi: 10.1016/s0891-0618(01)00133-8. PMID: 11522440. 13: Wayment HK, Schenk JO, Sorg BA. Characterization of extracellular dopamine clearance in the medial prefrontal cortex: role of monoamine uptake and monoamine oxidase inhibition. J Neurosci. 2001 Jan 1;21(1):35-44. doi: 10.1523/JNEUROSCI.21-01-00035.2001. PMID: 11150317; PMCID: PMC6762449. 14: Abidi SM, Nizami WA. Monoamine oxidase in amphistomes and its role in worm motility. J Helminthol. 2000 Dec;74(4):283-8. doi: 10.1017/s0022149x0000041x. PMID: 11138015. 15: Klegeris A, McGeer PL. R-(-)-Deprenyl inhibits monocytic THP-1 cell neurotoxicity independently of monoamine oxidase inhibition. Exp Neurol. 2000 Dec;166(2):458-64. doi: 10.1006/exnr.2000.7517. PMID: 11085911. 16: Stone TW, Behan WM, MacDonald M, Darlington LG. Possible mediation of quinolinic acid-induced hippocampal damage by reactive oxygen species. Amino Acids. 2000;19(1):275-81. doi: 10.1007/s007260070059. PMID: 11026499. 17: Leblond H, Menard A, Gossard JP. Bulbospinal control of spinal cord pathways generating locomotor extensor activities in the cat. J Physiol. 2000 May 15;525 Pt 1(Pt 1):225-40. doi: 10.1111/j.1469-7793.2000.t01-1-00225.x. PMID: 10811739; PMCID: PMC2269924. 18: Sikiric P, Separovic J, Buljat G, Anic T, Stancic-Rokotov D, Mikus D, Marovic A, Prkacin I, Duplancic B, Zoricic I, Aralica G, Lovric-Bencic M, Ziger T, Perovic D, Rotkvic I, Mise S, Hanzevacki M, Hahn V, Seiwerth S, Turkovic B, Grabarevic Z, Petek M, Rucman R. The antidepressant effect of an antiulcer pentadecapeptide BPC 157 in Porsolt's test and chronic unpredictable stress in rats. A comparison with antidepressants. J Physiol Paris. 2000 Mar- Apr;94(2):99-104. doi: 10.1016/s0928-4257(00)00148-0. PMID: 10791689. 19: Porsolt RD, Roux S, Drieu K. Evaluation of a ginkgo biloba extract (EGb 761) in functional tests for monoamine oxidase inhibition. Arzneimittelforschung. 2000 Mar;50(3):232-5. doi: 10.1055/s-0031-1300191. PMID: 10758773. 20: Behan WM, McDonald M, Darlington LG, Stone TW. Oxidative stress as a mechanism for quinolinic acid-induced hippocampal damage: protection by melatonin and deprenyl. Br J Pharmacol. 1999 Dec;128(8):1754-60. doi: 10.1038/sj.bjp.0702940. PMID: 10588931; PMCID: PMC1571800.